Table 2.
Systemic and local solicited adverse events within 28 days after single vaccine dose (110 participants).
| Total | Grade 1 | Grade 2 | |
|---|---|---|---|
| Any symptom | 74 (67·2) | 73 (66·4) | 6 (5·5) |
| Any injection-site symptoms | 7 (6·4) | 6 (5·5) | 1 (0·9) |
| Pain in injection site | 6 (5·5) | 5 (4·5) | 1 (0·9) |
| Redness | 1 (0·9) | 1 (0·9) | 0 |
| Any systemic symptoms | 72 (65·5) | 71 (64·5) | 5 (4·5) |
| Flu-like syndrome | 54 (49·1) | 51 (46·4) | 3 (2·7) |
| Fatigue | 6 (5·5) | 6 (5·5) | 0 |
| Headache | 5 (4·5) | 5 (4·5) | 0 |
| Muscle and joint pain | 5 (4·5) | 5 (4·5) | 0 |
| Hyperthermia | 5 (4·5) | 3 (2·7) | 2 (1·8) |
| Chills | 5 (4·5) | 5 (4·5) | 0 |
| Decreased appetite | 4 (3·6) | 4 (3·6) | 0 |
| Rash | 3 (2·7) | 3 (2·7) | 0 |
| Hidrosis | 3 (2·7) | 3 (2·7) | 0 |
| Dizziness | 2 (1·8) | 2 (1·8) | 0 |
| Diarrhoea | 1 (0·9) | 1 (0·9) | 0 |
| Abdominal pain | 1 (0·9) | 1 (0·9) | 0 |
| Raised blood pressure | 1 (0·9) | 1 (0·9) | 0 |
| Lymphadenopathy | 1 (0·9) | 1 (0·9) | 0 |
| Insomnia | 1 (0·9) | 1 (0·9) | 0 |
| Drowsiness | 1 (0·9) | 1 (0·9) | 0 |
| Nasal congestion | 1 (0·9) | 1 (0·9) | 0 |
| Hypaesthesia | 1 (0·9) | 1 (0·9) | 0 |
The table shows the total number (%) of volunteers who developed solicited adverse events, based on the severity: mild [grade 1], moderate [grade 2], no serious [grade 3] adverse events were reported. Some volunteers had several adverse events of different degrees of severity.